AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Wet Age Related Macular Degeneration (AMD) Disease Insights and Market Forecasts Report 2020-2026 - ResearchAndMarkets.com

January 6, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Jan 6, 2021--

The “Wet Age - Related Macular Degeneration (Amd) - Disease Insights and Market Forecasts to 2026” report has been added to ResearchAndMarkets.com’s offering.

“Wet age-related macular degeneration (AMD): Disease Insights and Market Forecasts to 2026” report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of AMD disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for AMD, drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2026.

ADVERTISEMENT

Disease Indication Overview:

This section of the report gives the overview of AMD disease indication in detail. The section highlights the basic definition, causes and symptoms of disease and details the types of AMD disease. Further details on the profile of AMD patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report. The report further highlights the multiple methods through which the patient can be diagnosed for AMD disease.

Epidemiology Forecasts to 2026:

This section of the report provides the overview of AMD diagnosed prevalent and treated patients in the US, EU5 and Japan market year wise starting from 2018 till 2026. The epidemiology numbers in the report have been derived based on numerous studies, survey reports and views of key opinion leaders.

Drugs Overview and Attribute Analysis:

This part of the report highlights the importance of factors influencing the physician prescription decisions in AMD disease including efficacy factors, Tolerability factors, Monitoring requirements and pricing factors.

The report further details the drugs prescribed or expected to be prescribed in AMD disease by the physicians in terms of details about the formulation, molecule, mode of administration and mechanism of action of the drugs, their patent and trial details and the expected impact of drug in the AMD market.

The report further conducts a detailed drug attribute analysis of the drugs currently prescribed or expected to be prescribed in the disease on the parameters of Efficacy, Safety and Tolerability, Convenience of Monitoring and Dosing and Drug’s coverage of the target patient pool.

ADVERTISEMENT

Drugs and Market Forecast to 2026:

The report in its last section provides sales and patient numbers forecast for the overall AMD market and drug wise forecasts from 2018 till 2026 at Global level and in the US, EU5, Australia and Canada markets. The forecasts are developed based on the detailed drug attribute analysis, as shared in the previous section.

Key Topics Covered:

1 Lists of Tables & Figures

2 Executive Summary

2.1 Key Metrics

3. Disease Overview

3.1 Disease Definition

3.2 Disease Etiology and Pathophysiology

3.2.1 Etiology

3.2.2 Pathophysiology

3.2.3 Impact on Quality of Life

3.3 Symptoms of the Disease

3.4 Disease Diagnosis

3.5 Treatment Guidelines

3.6 Key unmet needs

4. Disease Epidemiology

4.1 Patient Number projections by Country

4.1.1 France

4.1.2 Germany

4.1.3 Italy

4.1.4 Spain

4.1.5 United Kingdom

4.1.6 United States

4.1.7 Japan

5 Physician’s Insights

5.1 Factors impacting a physician’s prescription decision:

5.1.1 Efficacy

5.1.2 Safety

5.1.3 Monitoring requirements

5.1.4 Pricing and Reimbursement

6 Competitive Assessment and Attribute Analysis - Key Therapies

6.1 Eylea

6.1.1 Overview

6.1.2 Patent Information

6.1.3 Clinical Status and Trial Details

6.1.4 Attribute Analysis

6.1.5 Impact of Drug on the market

6.2 Lucentis

6.3 OPT-302

6.4 Beovu

6.5 Lytenava

6.6 KSI-301

6.7 RGX-314

7. Pipeline Assessment

7.1 Overview

7.2 Strategic Review of the Pipeline

7.3 Pipeline analysis by Phases of Development

7.3.1 NDA/BLA Filed

7.3.2 Phase III Pipeline

7.3.3 Phase II Pipeline

7.3.4 Phase I Pipeline

7.3.5 Preclinical Pipeline

7.3.6 Discovery Pipeline

7.4 Pipeline Analysis by Mechanism of Action

7.5 Pipeline Analysis by Novelty of Mechanism of Action

7.6 Suspended and Terminated products

8. Market Outlook

8.1 Major Markets Overview

8.1.1 Sales Forecast 2018-2026

8.1.2 Patient Forecast 2018-2026

8.2 Analysis by Country Sales and Patients forecast 2018-2026

8.2.1 France

8.2.2 Germany

8.2.3 Italy

8.2.4 Spain

8.2.5 United Kingdom

8.2.6 United States

8.2.7 Japan

8.3 Key events

8.4 Key Growth Drivers and Barriers

9 Sales and Patient Forecast for Key Drugs Forecasts till 2026

9.1 Eylea

9.1.1 Value sales in USD for AMD Disease

9.1.2 Value sales by key Geographies in USD

9.1.3 Absolute Patient Numbers in AMD Disease

9.1.4 Patient Numbers by key Geographies

9.2 Lucentis

9.3 OPT-302

9.4 Beovu

9.5 Lytenava

9.6 KSI-301

9.7 RGX-314

10. Appendix

Companies Mentioned

  • Novartis
  • Kodiak Sciences
  • REGENXBIO
  • Outlook therapeutics
  • Regeneron Pharmaceuticals
  • Bayer
  • Santen pharmaceuticals
  • Roche

For more information about this report visit https://www.researchandmarkets.com/r/wa7soy

View source version on businesswire.com:https://www.businesswire.com/news/home/20210106005416/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH OTHER HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 01/06/2021 06:24 AM/DISC: 01/06/2021 06:25 AM

http://www.businesswire.com/news/home/20210106005416/en